129 related articles for article (PubMed ID: 1821698)
1. Psychotropic effects of ritanserin, a selective S2 antagonist: an open study.
Strauss WH; Klieser E
Eur Neuropsychopharmacol; 1991 May; 1(2):101-5. PubMed ID: 1821698
[TBL] [Abstract][Full Text] [Related]
2. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial.
Duinkerke SJ; Botter PA; Jansen AA; van Dongen PA; van Haaften AJ; Boom AJ; van Laarhoven JH; Busard HL
Br J Psychiatry; 1993 Oct; 163():451-5. PubMed ID: 7902766
[TBL] [Abstract][Full Text] [Related]
3. Study to establish the indication for the selective S2 antagonist ritanserin.
Klieser E; Strauss WH
Pharmacopsychiatry; 1988 Nov; 21(6):391-3. PubMed ID: 3149751
[TBL] [Abstract][Full Text] [Related]
4. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia.
Wiesel FA; Nordström AL; Farde L; Eriksson B
Psychopharmacology (Berl); 1994 Feb; 114(1):31-8. PubMed ID: 7846205
[TBL] [Abstract][Full Text] [Related]
5. Treating negative symptoms.
Bailey P; Duval F; Macher JP
Br J Psychiatry; 1994 May; 164(5):699-700. PubMed ID: 7921730
[No Abstract] [Full Text] [Related]
6. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms.
Abi-Saab W; Seibyl JP; D'Souza DC; Karper LP; Gueorgueva R; Abi-Dargham A; Wong ML; Rajhans S; Erdos JP; Heninger GR; Charney DS; Krystal JH
Psychopharmacology (Berl); 2002 Jun; 162(1):55-62. PubMed ID: 12107618
[TBL] [Abstract][Full Text] [Related]
7. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
[TBL] [Abstract][Full Text] [Related]
8. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin.
Bersani G; Pozzi F; Marini S; Grispini A; Pasini A; Ciani N
Acta Psychiatr Scand; 1991 Apr; 83(4):244-8. PubMed ID: 1903019
[TBL] [Abstract][Full Text] [Related]
9. Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial.
Akhondzadeh S; Mohajari H; Reza Mohammadi M; Amini H
BMC Psychiatry; 2003 Jun; 3():7. PubMed ID: 12816549
[TBL] [Abstract][Full Text] [Related]
10. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
Bersani G; Grispini A; Marini S; Pasini A; Valducci M; Ciani N
Clin Neuropharmacol; 1990 Dec; 13(6):500-6. PubMed ID: 2125857
[TBL] [Abstract][Full Text] [Related]
11. Effects of amperozide in schizophrenia. An open study of a potent 5-HT2 receptor antagonist.
Axelsson R; Nilsson A; Christensson E; Björk A
Psychopharmacology (Berl); 1991; 104(3):287-92. PubMed ID: 1924636
[TBL] [Abstract][Full Text] [Related]
12. The treatment of negative symptoms: pharmacological and methodological issues.
Carpenter WT
Br J Psychiatry Suppl; 1996 May; (29):17-22. PubMed ID: 8733819
[No Abstract] [Full Text] [Related]
13. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs.
Mauri MC; Moliterno D; Rossattini M; Colasanti A
Schizophr Res; 2008 Feb; 99(1-3):7-12. PubMed ID: 18055177
[TBL] [Abstract][Full Text] [Related]
14. Lessons from MATRICS.
Marder SR
Schizophr Bull; 2011 Mar; 37(2):233-4. PubMed ID: 21325472
[No Abstract] [Full Text] [Related]
15. Measurement of depression and negative symptoms in schizophrenia.
Goldman RS; Tandon R; Liberzon I; Greden JF
Psychopathology; 1992; 25(1):49-56. PubMed ID: 1351305
[TBL] [Abstract][Full Text] [Related]
16. [Risperdal: a new hope for schizophrenic patients?].
Fortschr Neurol Psychiatr; 1994 May; 62(5 Suppl):1-4. PubMed ID: 9131061
[No Abstract] [Full Text] [Related]
17. Effects of ritanserin on sleep disturbances of dysthymic patients.
Paiva T; Arriaga F; Wauquier A; Lara E; Largo R; Leitao JN
Psychopharmacology (Berl); 1988; 96(3):395-9. PubMed ID: 3146774
[TBL] [Abstract][Full Text] [Related]
18. BPRS syndrome scales during the course of an episode of psychiatric illness.
Silverstein ML; Mavrolefteros G; Close D
J Clin Psychol; 1997 Aug; 53(5):455-8. PubMed ID: 9257223
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
Lee KU; Jeon YW; Lee HK; Jun TY
Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
[TBL] [Abstract][Full Text] [Related]
20. A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline.
Nappi G; Sandrini G; Granella F; Ruiz L; Cerutti G; Facchinetti F; Blandini F; Manzoni GC
Headache; 1990 Jun; 30(7):439-44. PubMed ID: 2119355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
